On April 28, 2018, the State Drug Administration of China conditionally approved the listing of a nine-valent human papilloma virus vaccine (HPV vaccine) for the prevention of cervical cancer. The HPV vaccine is the first vaccine in the world to include cancer as an indication in its instructions. At this… Continue Reading Nine-valent Cervical Cancer Vaccine Listed in China

Dilemma More than 10 million people worldwide suffer from cancer each year. Although the incidence of Alzheimer’s disease is not as good as that of cancer, there are more than 40 million patients worldwide. One disease causes the patient to die from the malignant proliferation of cells, while the other… Continue Reading Alzheimer’s disease drug development difficulties (7)

Microglia In addition to neurons, there is another type of cell: glial cells. There are three main types of glial cells in the brain: astrocytes that provide support for mutual communication between neurons, oligodendrocytes that surround an axon to form an insulating myelin sheath structure, and microglial cells. Microglia are… Continue Reading Alzheimer’s disease drug development difficulties (6)

Targeted Tau protein The amyloid hypothesis is not only supported by numerous experimental data. From the point of view of new drug development, the amyloid protein hypothesis can also provide practical new drug targets, because whether it is to develop monoclonal antibodies targeting plaques or plaques or to design BACE… Continue Reading Alzheimer’s disease drug development difficulties (5)

Remove starch protein At the end of the last century, the theory of amyloid protein had already had many supporters, and Athena Neurosciences, a Los Angeles-based biotechnology company, took the lead in the process of targeting amyloid protein. Their strategy is simple but also very bold: Develop a vaccine to… Continue Reading Alzheimer’s disease drug development difficulties (4)

Three theories At the end of the last century, we had a clearer understanding of the disease characteristics of Alzheimer’s disease, such as plaque and tangles, neuronal death, and memory decline. But where did the disease come from and how did it start? Alzheimer’s disease progresses very slowly. There are… Continue Reading Alzheimer’s disease drug development difficulties (3)

The first drug From the early to the early 1960s, scopolamine was used as an analgesic for maternal delivery. Scopolamine traps people in a semi-anesthetic state, leaving the patient awake while losing the ability to sense pain. However, during the course of medication, doctors found an interesting phenomenon: After giving… Continue Reading Alzheimer’s disease drug development difficulties (2)

Lost memory On November 3, 1906, a psychiatrist from Munich, Alois Alzheimer, reported a strange case at the conference of psychiatrists in southwest Germany in Tübingen. After the report was over, the audience was silent. What he had hoped for was a heated discussion. After all, nearly 100 people sat… Continue Reading Alzheimer’s disease drug development difficulties (1)

On April 27, Roche announced that Roche and its holding company, Foundation Medicine, Inc., have signed a cooperation agreement with Dean Diagnostic Technology Group Co., Ltd. (hereinafter referred to as “Dean Diagnostics”). They will work together to promote the individualized treatment of cancer in China. According to the cooperation agreement,… Continue Reading Roche inspected Dean’s diagnosis and introduced “general genomic sequencing analysis service” to jointly promote the individualized diagnosis and treatment of Chinese tumors.